San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, Shoreline Biosciences is raising $140,000,000.00 in new funding. Sources indicate as part of senior management Chairman, Kleanthis Xanthopoulos played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Shoreline Biosciences
Shoreline Biosciences is developing clinically effective allogeneic, off-the-shelf, targeted, and standardized immunotherapies using intelligently engineered induced Pluripotent Stem Cell (iPSC)-derived NK cells and macrophages for serious diseases. Shorelines proprietary cell therapy platform is based on deep expertise in iPSC differentiation methods and genetic programming of the IL-15/CISH pathway for enhanced persistence and tumor killing. In addition, the company aims to restore tissue homeostasis and function by introducing engineered macrophages for fibrotic and inflammatory pathologies. Shoreline has developed expertise that allows for efficient and cost-effective manufacturing of these cells. We are committed to scientific and clinical excellence and are passionate about bringing transformative therapies to patients in critical need.

To learn more about Shoreline Biosciences, visit http://www.shorelinebio.com/

Contact:
Kleanthis Xanthopoulos, Chairman
858-247-7033
https://www.linkedin.com/in/kleanthis-g-xanthopoulos-a4195210/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved